Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May:137:111254.
doi: 10.1016/j.biopha.2021.111254. Epub 2021 Jan 28.

Targets and strategies for vaccine development against SARS-CoV-2

Jonaid Ahmad Malik  1 , Almas Hanif Mulla  2 , Tahmeena Farooqi  3 , Faheem Hyder Pottoo  4 , Sirajudheen Anwar  5 , Kannan R R Rengasamy  6
Affiliations
Review

Targets and strategies for vaccine development against SARS-CoV-2

Jonaid Ahmad Malik et al. Biomed Pharmacother. 2021 May.

Abstract

The SARS-CoV-2, previously called a novel coronavirus, that broke out in the Wuhan city of China caused a significant number of morbidity and mortality in the world. It is spreading at peak levels since the first case reported and the need for vaccines is in immense demand globally. Numerous treatment and vaccination strategies that were previously employed for other pathogens including coronaviruses are now being been adopted to guide the formulation of new SARS-CoV-2 vaccines. Several vaccine targets can be utilized for the development of the SARS-CoV-2 vaccine. In this review, we highlighted the potential of various antigenic targets and other modes for formulating an effective vaccine against SARS-CoV-2. There are a varying number of challenges encountered during developing the most effective vaccines, and measures for tackling such challenges will assist in fast pace development of vaccines. This review will give a concise overview of various aspects of the vaccine development process against SARS-CoV-2, including 1) potential antigen targets 2) different vaccination strategies from conventional to novel platforms, 3) ongoing clinical trials, 4) varying challenges encountered during developing the most effective vaccine and the futuristic approaches.

Keywords: Antigen targets; COVID-19; Clinical trials; Pandemic; SARS-CoV-2 vaccine; Vaccine.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

None
Graphical abstract
Fig. 1
Fig. 1
Vaccination strategies for COVID 19.
Fig. 2
Fig. 2
Trivalent eVLP containing three different structural protein components.
See this image and copyright information in PMC

References

    1. Chan J.F.W., Yuan S., Kok K.H., To K.K.W., Chu H., Yang J., Xing F., Liu J., Yip C.C.Y., Poon R.W.S., Tsoi H.W., Lo S.K.F., Chan K.H., Poon V.K.M., Chan W.M., Ip J.D., Cai J.P., Cheng V.C.C., Chen H., Hui C.K.M., Yuen K.Y. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020 doi: 10.1016/S0140-6736(20)30154-9. - DOI - PMC - PubMed
    1. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z., Yu T., Xia J., Wei Y., Wu W., Xie X., Yin W., Li H., Liu M., Xiao Y., Gao H., Guo L., Xie J., Wang G., Jiang R., Gao Z., Jin Q., Wang J., Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 doi: 10.1016/S0140-6736(20)30183-5. - DOI - PMC - PubMed
    1. Wu S.C. Progress and concept for COVID-19 vaccine development. Biotechnol. J. 2020 doi: 10.1002/biot.202000147. - DOI - PMC - PubMed
    1. Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., Niu P., Zhan F., Ma X., Wang D., Xu W., Wu G., Gao G.F., Tan W. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 2020 doi: 10.1056/NEJMoa2001017. - DOI - PMC - PubMed
    1. Malik J.A., Maqbool M. COVID-19: An overview of cuurent scenario. CellMed Orthocellular Med. Pharm. Assoc. 2020;10 doi: 10.5667/CellMed.2020.0021. - DOI

Substances